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ABSTRACT 
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Coronary artery disease (CAD), the number one cause of death in the United States, has 
traditionally been combated by reactionary diagnostics. However, the current healthcare dynamic 
is shifting towards a preventative approach, which aims to treat disease prior to the manifestation 
of symptoms. A minimally invasive diagnostic method which provides insight into an 
individual’s blood chemistry has the potential to facilitate this transition. This study analyzes the 
protein chemistry of human blood serum in order to differentiate between CAD and Non-CAD 
serum, with the goal of discovering potential CAD biomarkers. The Beckman/Coulter P/ACE 
MDQ Capillary Electrophoresis System was coupled with a commercial SDS-Gel based buffer 
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system in order to achieve highly resolved serum protein spectrums. Electropherograms for 
nineteen participants were analyzed in 32 Karat™ Software by integrating protein peak areas, 
which were then normalized using an internal standard. Based on these integrations, a Linear 
Discriminant Analysis (LDA) algorithm was generated using OriginPro 8.6 Data Analysis and 
Graphing Software for the purpose of distinguishing between CAD and Non-CAD individuals. 
Cohorts of twelve CAD and seven Non-CAD participants were used for training purposes. This 
training data was classified with 100% accuracy, and an obtained p-value of 0.00332 indicated a 
significant difference between the CAD and Non-CAD participants’ peak distributions. This 
study establishes the utilization of capillary gel electrophoresis techniques for serum 
classification purposes, and ultimately points toward the development of a new, minimally 
invasive diagnostic tool for CAD based on blood protein chemistry rather than symptom onset. 
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NOMENCLATURE 
 
CAD: Coronary Artery Disease 
CGE: Capillary Gel Electrophoresis 
HDL: High Density Lipoprotein 
IBC: Institutional Biosafety Committee 
ID: Internal Diameter 
IRB: Institutional Review Board 
LDA: Linear Discriminant Analysis 
LDL: Low Density Lipoprotein 
MW: Molecular Weight 
PI: Principal Investigator 
CDA: Canonical Discriminant Analysis 
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CHAPTER I 
INTRODUCTION 
 
As the number one cause of death in the United States, CAD takes the lives of approximately 
380,000 Americans every year (1). Many of these deaths can be attributed to the progressive and 
typically irreversible nature of plaque build-up within the arteries (2). Due to current reactionary 
medical tactics, CAD-afflicted individuals often suffer from advanced stages of the disease that 
are difficult to reverse. Current heart disease prediction models have extremely low accuracy, 
debilitating the advancement towards early heart disease detection. The Framingham Study 
estimates the risk for CAD and myocardial infarction based on total cholesterol levels and other 
factors such as systolic blood pressure. It both underestimates and overestimates the risk of 
patients with and without heart disease respectively, due to poor sensitivity and specificity (3,4). 
It is evident that a new technique to identify heart disease at pre-symptomatic stages is necessary 
to eliminate the life-threatening manifestations that are common-place in today’s society.  
 
In light of this, recent research has attempted to investigate the subtle changes in chemistry that 
are ultimately responsible for the gross anatomical and physiological changes associated with 
disease development (5). Analysis of specific chemical components, known as biomarkers, have 
been shown to play a key role in the identification and assessment of a given disease (6,7). This 
pilot study capitalizes on the myriad of proteins in human blood serum in the hopes of 
identifying chemical changes that may be associated with CAD development. 
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CHAPTER II 
METHODS 
 
After obtaining Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) 
approval (IRB2014-0375M and IBC2013-161), a library of human serum samples of CAD and 
Non-CAD participants were run through the P/ACE MDQ Capillary Electrophoresis System in 
order to obtain electropherograms displaying the protein peaks of each separation. 
 
Analysis of protein chemistry in human blood serum was performed by using the 
Beckman/Coulter PACE MDQ Capillary Electrophoresis System in capillary gel electrophoresis 
(CGE) mode. The Beckman/Coulter System incorporates the 32 Karat™ Software, which 
provides a detailed analysis of each sample in the form of an electropherogram.  
 
Materials 
All capillaries, buffers, protein standard and wash solutions were obtained from the Beckman 
Coulter SDS-MW Kit (# 390953). Contents of the kit that were used in the analyses include 
capillaries of 50 µm I.D. bare-fused silica, a proprietary formulation of SDS-MW Gel Buffer (pH 
8), 0.2% SDS, SDS-MW Sample Buffer (100 mM Tris-HCl pH 9.0, 1%SDS), SDS-MW Size 
Standard—referred to as the MW ladder (10 to 225 kDa, 16 mg/mL), Acidic Wash Solution (0.1 
N HCl), and Basic Wash Solution (0.1 N NaOH). β-mercaptoethanol was acquired from Sigma-
Aldrich (PN M6250). Twelve CAD and seven Non-CAD clinical serum samples were obtained 
from the -85°C sample repository of the Laboratory for Cardiovascular Chemistry (LCC).  
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Human Serum Collection 
The serum samples were acquired from study participants at Scott & White Hospital in Temple, 
Texas with informed consent. All participants were of Caucasian race and their ages ranged from 
44-81 years old. These participants were clinically diagnosed with the presence or absence of 
CAD by their medical histories (e.g, coronary artery bypass graft(s), angioplasty/stent(s)) or 
unremarkable angiographies, respectively. The participants underwent a 12-hour fast before the 
blood was collected into 9.5 mL VacutainerTM tubes which had a silica activator and polymer gel 
(#366510, Beckton Dickinson Systems). The sera were isolated from the erythrocytes through 
centrifugation at 3200 rpm at 5oC for 20 minutes. Then, the supernatant was aspirated into 500 
µL Eppendorf tubes. These sample tubes were stored at -80oC preceding the sera analysis.  
 
Separation Conditions 
The CGE conditions for all separations were fixed with a wavelength of 214 nm and a stable 
system temperature of 25.0°C. A capillary length of 31.2 cm was used, with a separation length 
of 21.0 cm, and an internal diameter of 50.0 µm. All samples were eluted through the capillary to 
the anode.  
 
Preparation of Molecular Weight Ladder 
A commercial molecular weight (MW) ladder standard was run prior to the separation of the 
nineteen serum samples in order to calibrate the instrument and ensure validity. The standard is 
comprised of seven proteins of known molecular weights: 10, 20, 35, 50, 100, 150, and 225 kDa. 
The peaks of the standard produced in the electropherogram were verified using scientific 
publications. The nineteen clinical samples and the MW ladder standard were prepared in the 
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Biosafety Level-2 Laboratory (BSL-2) and analyzed using the following CGE method to produce 
electropherograms. 
 
The MW ladder run was prepared by adding 10 µL of the commercial MW ladder standard to 40 
µL of Sample Buffer. Following the addition of 2 µL of β-mercaptoethanol, the mixture was 
heated for five minutes in a 95℃ water bath. After heating, the sample was allowed to de-gas in 
a water bath sonicator for five minutes. The standard was then placed in the sample tray and four 
rinses of the capillary were performed. The capillary was successively washed with 0.1N NaOH 
for three minutes at 70.0 psi, 0.1N HCl for one minute at 70.0 psi, distilled water for one minute 
at 70.0 psi, and lastly sodium dodecyl sulfate (SDS) gel rinse for ten minutes at 70.0 psi.   
 
After the capillary rinse was completed, a voltage of 5.0 kV was applied for a duration of 20.0 
seconds during the sample injection in order to reverse the polarity, then a voltage of 15.0 kV 
was applied for 45.00 minutes separated the proteins of the MW ladder. Finally, an auto-zero 
function was performed five minutes into the separation. The separation data was recorded 
throughout the run using the 32 Karat™ Software, generating electropherograms comprised of 
separated protein peaks. 
	  
Human Sera Preparation 
For the preparation of the serum samples, 25 µL of the patient serum was added to 25 µL of 
Sample Buffer. The method used for the MW ladder separation was implemented for the analysis 
of individual serum samples, excluding the addition of β-mercaptoethanol and exposure to a hot 
water bath.  These exclusions were made to preserve integrity of the serum proteins to prevent 
the coagulation of the albumin and other proteins when exposed to high temperatures.  
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Analysis of Serum 
After acquiring the serum electropherograms with the 32 Karat™ Software, a double-peak 
alignment of internal markers was performed for each serum sample using the software’s 
‘Stretch’ operation. This operation was employed to negate fluctuation in the actual migration 
times of each separation which is a caveat to using gel systems. A consistent, characteristic divet 
with an actual migration time of approximately 8.5 minutes was aligned at the 10-minute mark 
and the consistently-predominating peak in the serum profiles was aligned at the 30-minute mark 
in each profile. A set of parameters, called ‘integration events’ (in the software), was utilized to 
obtain the integrated area of each individual protein peak. The integration events consist of 
setting the width to 0.2 and the threshold to 75 for the duration of the separation and turning the 
integration off for the first eight minutes of the separation. The areas of these peaks were 
manually inputted based on their relative retention times into an Excel file used as a database. 
Peaks were recorded in six-second intervals (every tenth of a minute), and were then assigned 
peak numbers based on their relation to the peaks of other serum profiles.  
 
A calibration curve was generated in the software by using the ‘Qualitative Analysis’ function 
based on the profile of the MW ladder. The migration times of each of the MW ladder proteins 
of known molecular weights were used to generate the curve. Analysis of the serum protein 
peaks against the curve provided an estimated molecular weight of the unknown serum proteins. 
 
Statistical Analysis of Serum 
Seven of the most distinct and prevalent peaks were chosen for statistical analysis based on 
migration time uniformity and a low signal to noise ratio. The data from these seven peaks was 
used to compare the CAD cohort profiles against the Non-CAD cohort profiles using OriginPro 
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8.6 Data Analysis and Graphing Software. A Canonical Discriminant Analysis (CDA) was 
performed on the seven peaks of the nineteen samples, which treated each peak as an 
independent variable and generated Canonical Coefficients, or coefficients used in a linear 
combination that, when applied to each sample’s peak data, produced a Canonical Score for that 
sample. The Canonical Score ultimately classified each sample as CAD or Non-CAD, based on 
its calculated value. Furthermore, a Linear Discriminant Analysis (LDA) was performed to 
determine the relative significance of each peak toward classifying samples as CAD or Non-
CAD. The nineteen participants were used as training data, and their classification by the CDA 
algorithm was compared to the actual CAD vs. Non-CAD statuses of the participants. A 
statistical analysis was performed on the results of the Canonical Scores in order to determine 
statistical significance. Lastly, a cross-validation analysis was performed to extrapolate our 
findings to a larger sample size. 
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CHAPTER III 
RESULTS 
 
The MW ladder protein standard is displayed in Figure 1. The ladder is composed of seven 
proteins of known molecular weights revealed by the seven predominate peaks of the 
electropherogram. The ladder demonstrates differences in elution time of the proteins due to their 
varying sizes as smaller, lighter proteins travel more quickly than heavier ones. Figure 2 shows 
the calibration curve of the MW ladder standard. A cubic fit type was used for the qualitative 
analysis and goodness of fit was calculated to be 0.999916. Using this calibration curve, the 
molecular weights of unknown peaks from other samples can be estimated. The migration times 
of the sera protein peaks were cross-referenced to this curve to approximate the sera protein 
sizes. Figure 3 shows a complete human serum electropherogram. The full 45-minute separation 
of the human proteomic display can be seen. The predominate peak in the serum profile is 
albumin—identified by both its predominating concentration in serum and based on where it 
falls on the calibration curve with regard to migration time. Albumin, which has a molecular 
weight of 66.5 kDa, came in at approximately 29 minutes. (8) Figure 4 shows the human serum 
sample separations of the seven Non-CAD participants. As reported in the Methods section, the 
profiles were aligned. The electropherograms were scaled to show the region between the 10-
minute and 36-minute marks as this region holds the majority of the protein peaks.  Figure 5 and 
Figure 6 display the human serum sample separations of the twelve CAD participants, which 
were aligned and scaled in the same way as the electropherograms in Figure 4.  
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Figure 1 Molecular weight ladder electropherogram displays seven proteins with known molecular weights: 10, 20, 35, 50, 100, 
150, and 225 kDa. 
 
	  
Figure 2 The calibration curve generated from the molecular weight ladder standard.  
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Figure 3 Human serum electropherogram of the full 45-minute separation 
 
Figures 4-6 enumerate the seven peaks of interest that were used to distinguish the CAD from 
the Non-CAD cohorts. These integrated peak areas were used for our statistical analysis to 
discriminate between the two cohorts. Peak numbers are not listed in numerical order because 
more than the seven peaks involved in the analysis were identified and assigned numbers. Two 
additional electropherograms have been added in the appendix showing the peaks numbered 1-
21.  The stacking of the electropherograms was performed to depict the differences in the 
profiles from one participant to another. 
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Figure 4 Serum Electropherograms for Non-CAD participants 1-7 with seven highlighted peaks of interest 
 
	  
Figure 5 Serum Electropherograms for CAD Participants 1-6 with seven highlighted peaks of interest 
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Figure 6 Serum Electropherograms for CAD Participants 7-12 with seven highlighted peaks of interest 
 
Figure 7 displays the Linear Discriminant Analysis coefficients for the CAD and Non-CAD 
cohorts. The dominance of the coefficient of peak #7 indicates that this peak is relatively 
influential on the deviation of CAD sample electropherogram peak areas from the Non-CAD 
sample peak areas. Alternately, peak #8 is less influential, as indicated by its small value for both 
the CAD and Non-CAD LDA function. 
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Figure 7 The LDA coefficients show each peak’s relative contribution to the discrimination between nineteen CAD and Non-
CAD participants	  
 
In the following figure, the Canonical Scores for the nineteen samples are displayed in Figure 7. 
Coronary artery disease classification is expressed as a value of -1 on the y-axis, while Non-CAD 
classification is expressed as a value of +1. The equation generated by the Canonical 
Discriminant Analysis (CDA) was applied to the peak data for each sample, as shown in 
Equation 1. A negative Canonical Score classified the sample as CAD, while a positive 
Canonical Score classified the sample as Non-CAD. A Canonical Score deviating farther away 
from 0, or the y-axis, shows a stronger classification and indicates that the particular sample 
exhibited typical CAD or Non-CAD indicators, while a Canonical Score close to 0 indicates a 
weaker classification. As shown in Figure 8, samples were classified as CAD or Non-CAD with 
100% accuracy by application of the CDA function. Furthermore, a cross-validation was 
performed using the training data as a substitute for the test data. An error rate of 12.5% resulted 
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from the cross-validation measure. It was discovered that the cross-validation has high 
specificity for Non-CAD participants and low sensitivity for CAD participants. This was 
determined by the 100% accurate classification of the Non-CAD participants and a 75% accurate 
classification of the CAD participants.  
Equation	  1 The Canonical Discriminant Analysis function (shown below), was applied to the peak data of the nineteen samples 
and generated a Canonical Score, ‘C’, which classified each sample as CAD or Non-CAD.	  
	  
 
	  
Figure 8. A score was generated for each of the nineteen-study participant by a canonical analysis of training data. A 
classification accuracy of 100% was obtained. 	  
 
Table 1. A p-value of 0.00332 was recorded, indicating a significant difference between the CAD and Non-CAD participants’ 
peak distributions. 
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Finally, the variation in peak areas was analyzed for statistical significance. Our null hypothesis, 
H0, stated that no difference exists between CAD and Non-CAD serum electropherogram peak 
area distributions. Our alternate hypothesis, HA, stated that a difference does exist between CAD 
and Non-CAD serum electropherogram peak area distributions. A Wilks-Lambda test was 
performed on the peak means and a p value of 0.00332 was obtained, allowing us to reject the 
null hypothesis. Thus, our results indicate a difference between the peak area distributions of 
CAD and Non-CAD serum sample electropherograms. 
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CHAPTER IV 
CONCLUSION 
 
In conclusion, the generated algorithms allow us to quantitatively compare CAD serum samples 
to Non-CAD serum samples. The resulting data from this comparison shows promise for CGE as 
a new technique for diagnosing CAD, as results were statistically significant. Thus, analyzing 
human sera with this method provides a simple, effective approach for distinguishing between 
CAD and Non-CAD individuals. 
 
Linear discriminant analysis of the electropherogram data allowed for the identification of 
several discrepancies between the CAD and Non-CAD cohorts. These differences in protein 
chemistry, upon further analysis, may prove to be associated and indicative of CAD 
development. Each of these peaks was compared via their assigned algorithm coefficients, as 
shown in Figure 7. The magnitude of each coefficient describes the weight each peak holds in 
the CAD versus Non-CAD designation relative to the respective peak integration values. Peak #7 
in particular is shown to be critical in the Non-CAD designation, with a coefficient four times 
larger than the other Non-CAD coefficients. Similarly, peak #7 plays the most significant role in 
the CAD designation, with a coefficient approximately two times larger than the other CAD 
coefficients. Identification of the protein responsible for peak #7 may reveal a critical biomarker 
for CAD and provide insight into the physiological changes caused by protein chemistry 
alterations. Peaks #11, #12, #13 and #14 carry a significant amount of weight in both the CAD 
and Non-CAD designations, while peaks #8 and #15 appear to be less significant.  As each of the 
peaks is identified, exploration into the effects of other variables on protein chemistry involved 
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in CAD and Non-CAD classification will be pursued, e.g., diet, physical activity, and therapies. 
Further examination of the relationship between protein biomarker patterns and the onset of 
CAD using our novel method may lead to the development of a minimally invasive CAD 
screening tool requiring only one drop of human serum. 
 
The future goal is to obtain a larger study population to validate the finding of the significant 
protein peaks in the serum samples. If the future findings are congruent with these results, the 
identification of each statistically significant peak will be pursued using protein standards. 
Furthermore, analysis of the protein profiles will be completed to calculate statistical coefficients 
of the protein peaks that were not examined in this study. This future examination may lead to 
the discovery of the other biomarkers for CAD.  
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